Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-26
2009-10-20
Aeder, Sean E (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07605142
ABSTRACT:
A method of treating a tumor (in particular osteosarcoma or Ewing's sarcoma) in a host by administering to a host or to the tumor cells an agent which inhibits cyclin G1 protein in an amount effective to inhibit cyclin G1 protein in tumor cells of the host. The agent may be an antisense polynucleotide which is complementary to at least a portion of a polynucleotide encoding cyclin G1 protein, or an antibody or fragment or derivative thereof which recognizes cyclin G1 protein. Also contemplated within the scope of the present invention are (i) the immortalization of cell lines by transducing cells with a polynucleotide encoding cyclin G1 protein; (ii) increasing the receptiveness of cells to retroviral infection by transducing cells with a polynucleotide encoding cyclin G1 protein; and (iii) the detection of cancer by detecting cyclin G1 protein or a polynucleotide encoding cyclin G1 protein in cells. In addition, the present invention provides expression vehicles, such as, for example, retroviral vectors and adenoviral vectors, which include polynucleotides which encode agents which inhibit cyclin G1 protein, and expression vehicles which include a polynucleotide encoding cyclin G1 protein.
REFERENCES:
patent: 4511713 (1985-04-01), Miller et al.
patent: 5272065 (1993-12-01), Inouye et al.
patent: 5449755 (1995-09-01), Roberts et al.
patent: 5514571 (1996-05-01), Riabowol
patent: 5543291 (1996-08-01), Keyomarsi et al.
patent: 5710022 (1998-01-01), Zhu et al.
patent: 5821234 (1998-10-01), Dzau
patent: 2002/0173538 (2002-11-01), Shiao
patent: WO 94/26888 (1994-11-01), None
patent: WO 02/18572 (2002-03-01), None
Byers, T. (CA Journal, vol. 49, No. 6, Nov./Dec. 1999).
Verma et al. (Nature 1997, 389: 239-242).
Amalfitano et al. (Current Gene Therapy 2002, 2: 111-133).
Pandha et al. (Current Opinion in Investigational Drugs 2000; 1(1): 122-134).
McNeish et al (Gene Therapy, 2004, 11:497-503).
McCormick (Nature Reviews, 2001, 1:130-141).
Wu et al (Oncol Rep, 1994, 1:705-711).
Griffin et al (J Biol Response Mod, Dec. 1988, 7(6):abstract).
Verma et al. (Nature 1997, 389: 239-242).
Amalfitano et al. (Current Gene Therapy 2002, 2: 111-133).
Pandha et al. (Current Opinion in Investigational Drugs 2000; 1(1): 122-134).
McNeish et al (Gene Therapy, 2004, 11:497-503).
McCormick (Nature Reviews, 2001, 1:130-141).
Wu et al (Oncol Rep, 1994, 1:705-711).
Griffin et al (J Biol Response Mod, Dec. 1988, 7(6):559-567).
Albers, et al. FKBP-Rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in Early G1 of an osteosarcoma cell. J. Bio. Chem. 1993; 268(30):22825-22829.
Baker, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990; 249: 912-915.
Baldin, et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993; 7(5):812-21.
Cohen, et al. The new genetic medicines. Scientific American. 1994; pp. 76-82.
Cripps, et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clinical Cancer Research. 2002; 8:2188-2192.
Draetta, G. F. Mammalian G1 cyclins. Curr. Opin, In Cell Biol. 1994; 6:842-846.
Gentry et al. Type 1 transforming growth factor beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells. Mol. Cell. Biol. 1987: 7(10):3418-3427.
Gordon, et al. Induction of apoptosis by a human antisense cyclin G1 (CYCGI) gene in human osteogenic sarcoma cells after retroviral vector-mediated transfer. Blood. 1995; 86(Supp. 1):244a, Abstract 964.
Grim, et al. Intracellular expression of the anti-erbB-2 sFv N29 fails to accomplish efficient target modulation. Biochem. and Biophys. Res. Comm. 1998; 250:699-703.
Grinstein, et al. Multiple octamer-binding proteins are targets for the cell cycle-regulated nuclear inhibitor I-92. DNA and Cell Biol. 1995; 14(6):493-500.
Grunhaus, et al. Adenoviruses as cloning vectors. Seminars in Virology. 1992; 3:237-252.
Haprer, et al. Inhibition of cyclin-dependent kinases by p21. Mal Biol. Cell. 1995; 6:387-400.
Hartwell, et al. Cell cyclin control and cancer. Science. 1994; 266:1821-1828.
Horne, et al. Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression. J. Biol. Chem. 1996; 271(11): 6050-6061.
Jones, et al. Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. Advanced Drug Delivery Reviews. 1998; 31:153-170.
Majors, J. E. Retroviral vectors—strategies and applications. Seminars in Virology. 1992; 3:285-295.
Marshall, et al. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clinical Colorectal Cancer. 2004; 4:268-274.
Okamoto, et al. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 1994; 13(19):4816-4822.
Oza, et al. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecological Oncology. 2003; 89:129-133.
Skotzko, et al. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Research. 1995; 55:5493-5498.
Tamura, et al. Cyclin G: a new mammalian cyclin with homology to fission yeast Cig1. Oncogene. 1993; 8:2113-2118.
Tolcher, et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clinical Cancer Research. 2002; 8:2530-2535.
Williams, et al. Identification of a novel cyclin-like protein in human tumor cells. Journal of Biological Chemistry. 1993; 268:8871-8880.
Wu, et al. Early G1 induction of p21/WAF1/CIP1 in synchronized osteosarcoma cells is independent of p53. Oncology Reports. 1995; 2:227-231.
Wu, et al. Molecular cloning of the human CYCG1 gene encoding a G-type cyclin: overexpression in a human osteosarcoma cells. Oncology Reports. 1994; 1(4):705-711.
Wu, et al. Sequential and progressive cyclin expression in human osteosarcoma cells: Diagnostic and the therapeutic implications. Int. J. Oncology. 1993; 3:859-867.
Xiong, et al. Human D-type cyclin. Cell. 1991; 65:691-699.
Zhu, et al. Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. J. Immune Methods. 1999; 231:207-222.
Anderson W. French
Gordon Erlinda M.
Hall Frederick L.
Aeder Sean E
University of Southern California
Wilson Sonsini Goodrich & Rosati
LandOfFree
Expression of cyclin G1 in tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Expression of cyclin G1 in tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression of cyclin G1 in tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4077189